Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Terbinafine Hydrochloride

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Source review pending Not FDA-approved for animals Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Source review pending
No refresh timestamp yet

Roxee is still reviewing source support for this medication profile.

FDA applications
Regulatory match pending
No refresh timestamp yet

Roxee has safety or ingredient evidence for this medication, but a regulatory product/application match is still pending.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:05 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Image coming soon
Terbinafine Hydrochloride

Terbinafine Hydrochloride

Drug type: Generic ingredient • Generic profile • Not FDA-approved for animals

Both 80% storefront ready

Species: Both

Approval status: Not FDA-approved as an animal drug. No FDA-approved animal-drug application is linked for this record. It may represent extra-label, human-drug, bulk-compounding, export-only, or otherwise unapproved animal-use source data; use only under veterinarian direction.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Terbinafine Hydrochloride

Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. Species commonly shown: Both.

Generic name
Terbinafine Hydrochloride
Species
Both
Completeness
80%
Validation
Incomplete

Indications / Uses

Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus.

Side Effects

Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus.

FAQ

Both

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Roxee still has limited plain-language guidance for this medication. Use the official documents and your veterinarian's instructions for product-specific details.

Used for:

Your vet decides this. Here's what owners typically ask/watch for.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Loss of appetite (1 reports)
  • Eosinophilia (1 reports)
  • Eosinopenia (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Loss of appetite
  • Eosinophilia
  • Eosinopenia

Most reported reactions:

  • Loss of appetite (1 reports)
  • Eosinophilia (1 reports)
  • Eosinopenia (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Manufacturer not confirmed
Identifiers:
NDC Package: 86032-057-01 NDC Product: 86032

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
13
Species represented
2
Grouped by Body System
Digestive (4) · Loss of appetite, Decreased appetite, Bloody diarrhoea Skin & allergy (2) · Hair loss at application site, Hair loss Neurologic (2) · Unsteady walking (ataxia), Circling - neurological disorder Behavior (1) · Behavioral disorder (unspecified) Other (23) · General pain, Falling, Excoriation
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1

Species coverage: Dog (17) Cat (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Non-serious - 1
Digestive Cat Serious - 1
Skin & allergy Dog Non-serious - 1
Skin & allergy Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Digestive Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Neurologic Cat Non-serious - 1
Digestive Dog Non-serious - 1
Behavior Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

1

FOI

0
No FOI links yet.

Terbinafine Hydrochloride SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Terbinafine Hydrochloride. Use the source link for the full official labeling record.
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:05 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Manufacturer mapping: Evereen Shanghai Biotechnology Ltd.
Case-reported brands (openFDA): MSK
Catalog species: Both
Safety (openFDA)
Top reactions: Dog 14 • Cat 0 • View
Case summaries: 2 (showing 2) • View
openFDA reports are unverified and do not prove causation.
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Top reaction signals
Loss of appetite (1) Eosinophilia (1) Eosinopenia (1) Enamel disorder (1) Decreased activity (1) Deafness (1) Claw / hoof / nail disorder NOS (1) Basophilia (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NDC Package: 86032-057-01 NDC Product: 86032
Package NDC Product NDC Form / Route Status
86032-057-01 86032 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Terbinafine Hydrochloride SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 21 Clinical 8 Manufacturer 0 Marketing 0
Current Field Facts
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Clinical, 2026-04-11)
  • manufacturer_name: Evereen Shanghai Biotechnology Ltd. (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-05-05)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-05-03)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-30)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-29)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-28)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-27)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-26)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-25)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-17)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Ataxia, Head tilt - ear disorder, Vomiting, Corneal ulcer, Nystagmus. (Official, 2026-04-15)
Recent Revisions
  • side_effects updated 2026-05-05 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-05-03 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-30 10:09 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-29 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-28 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-27 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-26 10:06 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-25 10:05 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-21 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-21 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-21 10:06 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-21 10:06 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-21 10:06 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-21 10:06 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-20 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-20 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-20 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-20 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-20 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-20 10:08 by curated_loader • Official FDA application reference for Senvelgo.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat Decreased appetite (1) • Cat Bloody diarrhoea (1) • Dog Appetite disorder NOS (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Hair loss at application site (1) • Dog Hair loss (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog Circling - neurological disorder (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog

Showing top 5 for Behavior.

Other
General pain (1) • Cat Falling (1) • Cat Excoriation (1) • Dog Erythema (1) • Dog Eosinophilia (1) • Dog
Show more (18)
Eosinopenia (1) • Cat Enamel disorder (1) • Dog Elevated temperature (1) • Dog Dull (1) • Dog Dilated pupils (1) • Dog Decreased activity (1) • Dog Deafness (1) • Dog Cough (1) • Dog Claw / hoof / nail disorder NOS (1) • Cat Basophilia (1) • Cat Balance problem (1) • Cat Balance impaired (1) • Cat Bacterial skin infection NOS (1) • Dog Application site haemorrhage (1) • Cat Application site erythema (1) • Cat Anisocoria (1) • Cat Abnormal radiograph finding (1) • Cat Abnormal cytology (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Terrier - Yorkshire, Female, 13 year, 6.12 kilogram • Drug: MSK, Unknown • Reactions: Partial lack of efficacy, Hair loss, Erythema, Papule, Excoriation… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072174
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 6.120 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Partial lack of efficacy Hair loss Erythema Papule Excoriation Skin scab Bacterial skin infection NOS Abnormal cytology
Outcomes: Ongoing

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Female, 5 month, 5.987 kilogram • Drug: MSK, Unknown • Reactions: Hair loss, Bacterial skin infection NOS, Ringworm, Vomiting, Cough… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-070191
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 5.00 Month
  • Weight: 5.987 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Hair loss Bacterial skin infection NOS Ringworm Vomiting Cough Bloody diarrhoea Behavioral disorder (unspecified) Lack of efficacy (bacteria) - Anaplasma
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.